PTEN Genetic Test: Cowden Syndrome, Cancer Risk, and Results

A PTEN genetic test looks for an inherited pathogenic variant in the PTEN tumor-suppressor gene. A positive germline result can confirm PTEN hamartoma tumor syndrome, an umbrella diagnosis that includes Cowden syndrome and several related presentations. The finding matters because PTEN variants can raise the lifetime risk of breast, thyroid, endometrial, kidney, and colorectal cancers while also explaining noncancerous findings such as a large head size, skin or mouth lesions, intestinal polyps, vascular abnormalities, and developmental differences.

Testing is usually performed on blood or saliva, although another tissue may be needed when mosaicism is suspected. A result does not predict exactly which health problems will occur or when they will appear. Instead, it helps clinicians set up organ-specific surveillance, discuss risk-reducing options, and offer targeted testing to relatives. The report should be interpreted with personal history, physical findings, family history, and the laboratory’s evidence for the specific variant.

• A positive PTEN result usually confirms an inherited cancer-predisposition syndrome and calls for lifelong, organ-specific surveillance.
• A negative result does not fully exclude PTEN-related disease when clinical features are strong or the test did not assess every variant type.
• A variant of uncertain significance should not be used by itself to diagnose Cowden syndrome or justify preventive surgery.
• PTEN-related cancer risk varies by organ, age, sex, family history, and possibly the type and location of the variant.
• Close relatives of a person with a confirmed germline PTEN variant can usually have focused testing for that exact familial variant.

Table of Contents

• What the PTEN Test Detects
• Who May Need PTEN Testing
• How Testing Is Performed
• Understanding PTEN Test Results
• Cancer Risks and Surveillance
• Family Planning and Relative Testing
• Limitations, Costs, and Next Steps

What the PTEN Test Detects

PTEN provides instructions for a protein that restrains cell growth through the PI3K-AKT-mTOR signaling pathway. It acts like a cellular brake. When one inherited copy of PTEN does not work properly, cells in several tissues may be more likely to form hamartomas, benign tumors, or cancers after additional changes occur.

A clinical PTEN test usually examines the gene for sequence variants and, when included, deletions or duplications involving one or more exons. Sequence analysis can identify many single-letter DNA changes and small insertions or deletions. Copy-number analysis looks for larger missing or extra segments that sequence analysis may miss. Some laboratories also assess the promoter region or use RNA studies when a suspected splice alteration needs clarification.

The test ordered for possible Cowden syndrome is a germline test. It asks whether the variant is present throughout the body and can be inherited. That differs from a PTEN alteration reported on somatic tumor testing. PTEN loss or mutation is common in many sporadic cancers, but a tumor-only finding does not automatically mean the person has PTEN hamartoma tumor syndrome. A genetics team may recommend confirmatory blood testing when a tumor report suggests a potentially inherited alteration.

PTEN hamartoma tumor syndrome, often shortened to PHTS, includes several historically named conditions:

• Cowden syndrome, commonly associated with adult-onset mucocutaneous findings, macrocephaly, hamartomatous growths, and increased cancer risks.
• Bannayan-Riley-Ruvalcaba syndrome, often recognized in childhood through macrocephaly, intestinal hamartomatous polyps, lipomas, and penile freckling.
• PTEN-related macrocephaly and neurodevelopmental presentations, which may include autism spectrum disorder, developmental delay, or intellectual disability.
• Less common PTEN-related overgrowth and vascular phenotypes.

These labels overlap. Two people with the same familial variant may have very different findings, even within one family. That variable expression is why genetic results must be paired with a detailed clinical assessment rather than interpreted as a fixed forecast.

Who May Need PTEN Testing

PTEN testing is considered when a person’s combination of cancers, benign growths, physical features, or family history fits a PTEN-related pattern. Testing may be ordered as a single-gene test when the presentation is highly characteristic, or as part of a hereditary cancer or overgrowth panel when several syndromes could explain the findings. A broader hereditary cancer gene panel can be useful when breast, thyroid, uterine, kidney, or colorectal cancers cluster without classic Cowden features.

Features that often prompt evaluation include:

• Breast cancer at a young age, bilateral breast cancer, or multiple primary cancers together with other PHTS findings.
• Follicular thyroid cancer, multiple thyroid nodules, or nonmedullary thyroid cancer in a suggestive personal or family pattern.
• Endometrial cancer, especially at an early age or with macrocephaly and mucocutaneous findings.
• Renal cell carcinoma, particularly when other Cowden-associated features are present.
• Numerous gastrointestinal hamartomatous, hyperplastic, adenomatous, or mixed-type polyps.
• Adult Lhermitte-Duclos disease, a dysplastic gangliocytoma of the cerebellum strongly associated with PHTS.
• Characteristic skin or oral findings such as multiple trichilemmomas, acral keratoses, oral papillomas, or extensive mucocutaneous lesions.
• Macrocephaly, generally defined clinically as a head circumference at or above the 97th percentile.
• A child with macrocephaly plus autism, developmental delay, penile freckling, vascular malformations, lipomas, or gastrointestinal polyps.
• A known PTEN pathogenic variant in a close relative.

A person does not need to have cancer to qualify for testing. In fact, identifying a familial variant before cancer develops creates the greatest opportunity for surveillance. Conversely, one common cancer alone usually does not prove a PTEN syndrome. Clinicians use formal diagnostic or testing criteria, but they also consider age, ancestry, pathology, head circumference, dermatologic examination, and the exact family pattern.

Genetic counseling before testing helps distinguish diagnostic testing from predictive testing. Someone with suggestive features is undergoing diagnostic evaluation. A healthy relative of a known carrier is usually having targeted predictive testing. The emotional and insurance implications may differ, even though the laboratory method can be similar.

How Testing Is Performed

Most germline PTEN tests use a blood sample or saliva collection. Blood is often preferred when a laboratory needs high-quality DNA or when there is concern that saliva may contain a mixture of cell types. No fasting is needed. Medications usually do not affect the DNA result.

The laboratory method depends on the order:

1. Sequence analysis reads the protein-coding portions of PTEN and nearby splice boundaries. It detects most small pathogenic variants.
2. Deletion and duplication analysis checks for larger missing or extra sections of the gene.
3. Multigene panel testing analyzes PTEN alongside other genes that can cause overlapping cancer or hamartoma syndromes.
4. Targeted familial-variant testing looks only for a previously identified variant and is usually faster and less expensive than full analysis.
5. Mosaicism evaluation may analyze a second tissue, such as cultured skin fibroblasts or affected tissue, if blood testing is negative but the phenotype remains compelling.

Results often take two to six weeks, although turnaround time varies by laboratory and test scope. Large panels may take longer. Insurance authorization may require documentation of clinical criteria, a three-generation family history, and a genetics consultation.

Before giving a sample, it is useful to gather pathology reports, prior genetic test reports, colonoscopy records, thyroid records, and relatives’ cancer diagnoses. The exact laboratory report from an affected relative is especially important. A statement that a family member “has the Cowden gene” is not enough for targeted testing; the testing laboratory needs the gene, DNA change, classification, and ideally the original report.

Testing minors is appropriate when a result can change childhood care. PTEN-related thyroid surveillance and developmental management can begin during childhood, so testing an at-risk child is different from testing for an adult-only condition. The timing should still be discussed with a pediatric genetics team that can address consent, preparation, and how the result will be explained over time.

Understanding PTEN Test Results

A PTEN report typically classifies each variant as pathogenic, likely pathogenic, uncertain, likely benign, or benign. The category reflects the strength of evidence that the DNA change disrupts gene function and causes disease. It does not describe the severity of the person’s current symptoms.

Positive: pathogenic or likely pathogenic variant

A pathogenic or likely pathogenic germline variant supports a diagnosis of PTEN hamartoma tumor syndrome when the laboratory and clinical setting are appropriate. “Likely pathogenic” generally means the evidence is strong but not quite at the highest certainty level; clinical management is usually the same as for a pathogenic result.

A positive result means:

• The person has an increased risk for the recognized PHTS-associated cancers and benign manifestations.
• Surveillance should follow a syndrome-specific plan rather than average-risk screening alone.
• Each biological child usually has a 50% chance of inheriting the variant because PHTS follows an autosomal dominant pattern.
• Parents, siblings, and adult children may benefit from targeted testing.

It does not mean cancer is present, inevitable, or already developing. It also does not specify the age of onset. Penetrance is high for some manifestations, but expression varies widely.

Negative result

A negative result has different meanings depending on the context. If the test specifically looked for a known familial PTEN variant and did not find it, the person is usually considered a true negative for that variant. Their PHTS-related risks generally return to those based on their own medical and non-PTEN family history.

If no familial variant is known, a negative full-gene test is less definitive. Possible explanations include:

• The person’s findings are caused by another gene.
• The causative variant lies in a region or variant class the assay does not detect well.
• Low-level mosaicism is absent from blood or below the test’s detection threshold.
• The clinical features are coincidental or represent a non-genetic condition.

A genetics professional may recommend panel testing, deletion analysis if not already done, reanalysis, another tissue, or clinical surveillance based on the phenotype.

Variant of uncertain significance

A VUS means current evidence cannot determine whether the change causes PHTS. It is not a positive diagnosis. Medical decisions should rely on the person’s clinical risk, not on the VUS alone. Testing unaffected relatives solely to see who carries a VUS is usually not helpful unless a genetics team is conducting a structured segregation study.

Laboratories may reclassify a VUS as more evidence accumulates. Keep contact information current with the ordering clinic and ask how updates are communicated. The principles in a genetic variant classification report are particularly important here because different variants in the same gene can have very different evidence.

Mosaic or uncertain-origin findings

Low variant allele fractions can indicate post-zygotic mosaicism, a blood-cell clone, sample quality issues, or technical artifacts. PTEN mosaicism can produce a milder or patchy phenotype, but risk assessment depends on which tissues carry the variant. Confirmation with another sample and review by a laboratory geneticist are often necessary.

Cancer Risks and Surveillance

Published risk estimates vary because studies use different referral populations, age ranges, and methods. People seen in specialty clinics may have more severe disease than unselected carriers, which can inflate lifetime estimates. Recent data still support substantial risks for several cancers, especially female breast, endometrial, thyroid, renal, and colorectal cancer. Exact percentages should be taken from current syndrome guidance and individualized rather than treated as guarantees.

A surveillance plan may include the following elements. Ages and intervals can differ among guidelines, countries, family histories, and updated evidence, so the treating genetics team should provide the final schedule.

Organ or issue	Common surveillance approach	Why it is used
Thyroid	Regular thyroid examination and ultrasound beginning in childhood or at diagnosis, with interval guided by findings and current recommendations	Thyroid nodules are common, and differentiated thyroid cancer can occur at young ages
Breast	Breast awareness, clinical evaluation, and earlier MRI-based screening; mammography is added according to age and guideline	Female breast cancer risk is substantially increased
Endometrium	Education about abnormal bleeding, prompt diagnostic evaluation, and individualized discussion of surveillance or risk-reducing surgery	Endometrial cancer risk is increased, while the benefit of routine screening tests remains uncertain
Kidneys	Periodic renal imaging, often MRI or ultrasound depending on protocol and patient factors	Renal cell carcinoma can be bilateral or multifocal and may occur earlier than in the general population
Colon and gastrointestinal tract	Colonoscopy beginning earlier than average-risk screening, with interval based on polyp burden and family history	Mixed polyp types and colorectal cancer occur more often in PHTS
Skin	Periodic dermatologic examination and assessment of changing lesions	Mucocutaneous findings support diagnosis, and some guidance includes melanoma awareness
Development and behavior	Developmental, educational, neurologic, and behavioral evaluation when indicated	Macrocephaly, autism, developmental delay, and other neurologic features may need support independent of cancer risk

Surveillance is not one-size-fits-all. A person with prior thyroid cancer needs cancer follow-up as well as PHTS surveillance. Someone with heavy polyp burden may need colonoscopy more often than a carrier with normal examinations. A relative’s very early cancer may justify starting a specific screening component earlier.

Risk-reducing mastectomy can be discussed with some women because of the high breast cancer risk, but it is elective and preference-sensitive. The decision should consider age, imaging findings, family experience, surgical risks, reconstruction options, and the person’s values. Risk-reducing hysterectomy may also be discussed after childbearing, particularly when other pelvic surgery is planned, but removal of the ovaries is not automatically required for PHTS because ovarian cancer is not a defining risk in the same way.

New symptoms should not wait for the next surveillance visit. A new breast lump, persistent abnormal uterine bleeding, blood in the urine, unexplained anemia, progressive swallowing difficulty, a rapidly enlarging neck mass, or focal neurologic symptoms warrants timely assessment. Surveillance lowers the chance of delayed detection; it does not replace diagnostic evaluation of symptoms.

Family Planning and Relative Testing

PTEN hamartoma tumor syndrome is autosomal dominant. A carrier has one altered copy and one working copy of PTEN in most cells. Each pregnancy has a 50% chance of inheriting the altered copy, regardless of the child’s sex. The child’s features cannot be predicted from the parent’s severity because expression can differ greatly.

Once a familial variant is known, relatives can have a focused familial variant test. Testing usually starts with first-degree relatives: parents, siblings, and children. If a parent tests positive, the result identifies which side of the family is at risk and allows testing to extend through that branch. If both parents test negative, the variant may have arisen de novo in the affected person, although parental mosaicism remains a small possibility.

A positive child may need thyroid surveillance, developmental assessment, and evaluation of physical findings. A negative child for the known familial variant generally does not need PHTS-specific surveillance. This distinction can spare unaffected relatives years of unnecessary imaging and worry.

Reproductive options include natural conception with testing during pregnancy, in vitro fertilization with preimplantation genetic testing for monogenic disease, use of donor egg or sperm, adoption, or conception without genetic testing. Prenatal diagnosis through chorionic villus sampling or amniocentesis can determine whether a fetus inherited the variant, but it cannot predict the eventual severity. These are personal choices, and nondirective genetic counseling is appropriate.

Family communication can be difficult because the result affects people who may have different views about testing. A genetics clinic can provide a family letter that states the gene, inheritance pattern, and how relatives can arrange testing without disclosing unnecessary medical details.

Limitations, Costs, and Next Steps

No PTEN test detects every possible disease mechanism. Standard assays may miss deep intronic variants, complex structural changes, low-level mosaicism, epigenetic changes, or variants in another gene. A laboratory’s reportable range and deletion-detection method should be reviewed when the clinical suspicion remains high.

Variant interpretation can also change. Databases grow, functional studies improve, and expert panels refine gene-specific criteria. A result from years ago may deserve re-review, especially if it was reported as a VUS or if testing used older technology. Reanalysis is different from repeating the test: reanalysis reinterprets existing data, while repeat testing may use a broader or more sensitive method.

Cost varies by country, laboratory, insurance plan, and whether testing is single-gene, panel-based, or targeted. Before testing, ask about prior authorization, self-pay pricing, family testing programs, and charges for counseling. In the United States, federal protections limit health-insurance and employment discrimination based on genetic information, but they do not cover every type of insurance, such as life, disability, or long-term-care coverage. Local rules differ.

After receiving the report, useful next steps are:

1. Review the exact variant and classification with a genetics professional.
2. Confirm whether the result is germline, somatic, mosaic, or uncertain in origin.
3. Build a written surveillance calendar that names the test, starting age, interval, and responsible clinician.
4. Obtain baseline evaluations for organs relevant to the person’s age and history.
5. Share a laboratory-based family letter with relatives who may benefit from testing.
6. Keep a copy of the report and update the genetics clinic when contact information changes.
7. Revisit the plan when guidelines, family history, or personal health changes.

The most useful PTEN result is one that leads to coordinated care. Primary care, genetics, oncology, endocrinology, gastroenterology, dermatology, gynecology, pediatrics, and other specialists may all participate, but one clinician should help track the overall plan so that surveillance is neither missed nor duplicated.

A written surveillance plan is especially helpful when care is divided among primary care, breast imaging, thyroid, dermatology, gastroenterology, and gynecology teams. The plan should name the person responsible for each screening test, the starting age, the interval, and what to do after an abnormal result. Keeping the original laboratory report prevents confusion about the exact variant when a relative seeks testing or the family changes health systems.

References

• PTEN Hamartoma Tumor Syndrome 2025 (Review)
• Cancer and Overgrowth Manifestations of PTEN Hamartoma Tumor Syndrome: Management Recommendations from the International PHTS Consensus Guidelines Working Group 2025 (Guideline)
• Update on Pediatric Surveillance Recommendations for PTEN Hamartoma Tumor Syndrome, DICER1-Related Tumor Predisposition, and Tuberous Sclerosis Complex 2025 (Guideline)
• Extended spectrum of cancers in PTEN hamartoma tumor syndrome 2025 (Review)
• Clinical Guidelines for Diagnosis and Management of Cowden Syndrome/PTEN Hamartoma Tumor Syndrome in Children and Adults—Secondary Publication 2023 (Guideline)
• Longitudinal Analysis of Cancer Risk in Children and Adults With Germline PTEN Variants 2023 (Cohort Study)

Disclaimer

This article provides general information about PTEN testing and does not replace individualized genetic counseling or medical care. Cancer-risk estimates and surveillance recommendations can change and must be adapted to the exact variant, age, sex, medical history, family history, and current clinical guidelines. Seek prompt medical evaluation for concerning symptoms rather than waiting for routine surveillance.